Compounds > pd 178390
Page last updated: 2024-11-13

pd 178390

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

PD 178390: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54687772
CHEMBL ID3186626
SCHEMBL ID7633268
MeSH IDM0350414

Synonyms (24)

Synonym
(2s)-2-[2-(4-aminophenyl)ethyl]-5-[2-tert-butyl-4-(hydroxymethyl)-5-methyl-phenyl]sulfanyl-4-hydroxy-2-isopropyl-3h-pyran-6-one
207736-05-8
ci-1029
pd 178390
pd178390 ,
2h-pyran-2-one, 6(s)-[2-(4-aminophenyl)ethyl]-3-[[2-(1,1-dimethylethyl)-4-(hydroxymethyl)-5-methylphenyl]thio]-5,6-dihydro-4-hydroxy-6-(1-methylethyl)-
2h-pyran-2-one, 6-[2-(4-aminophenyl)ethyl]-3-[[2-(1,1-dimethylethyl)-4-(hydroxymethyl)-5-methylphenyl]thio]-5,6-dihydro-4-hydroxy-6-(1-methylethyl)-, (6s)-
NCGC00248031-01
NCGC00254371-01
dtxcid6027262
dtxsid8047262 ,
tox21_300429
cas-207736-05-8
vdh375trl9 ,
2h-pyran-2-one, 6-(2-(4-aminophenyl)ethyl)-3-((2-(1,1-dimethylethyl)-4-(hydroxymethyl)-5-methylphenyl)thio)-5,6-dihydro-4-hydroxy-6-(1-methylethyl)-, (6s)-
2h-pyran-2-one, 6(s)-(2-(4-aminophenyl)ethyl)-3-((2-(1,1-dimethylethyl)-4-(hydroxymethyl)-5-methylphenyl)thio)-5,6-dihydro-4-hydroxy-6-(1-methylethyl)-
unii-vdh375trl9
SCHEMBL7633268
ZUBPKHVCBGWWGO-NDEPHWFRSA-N ,
(s)-6-[2-(4-aminophenyl)ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methylphenylsulfanyl)-4-hydroxy-6-isopropyl-5,6-dihydropyran-2-one
CHEMBL3186626
pd-178390
Q27291773
AKOS040751178

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The in vitro resistance profile, inhibitory activities against cytochrome P450 isozymes and pharmacokinetic properties of inhibitor 15S will be discussed."( Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.
Boyer, FE; Brodfuehrer, J; Domagala, JM; Ellsworth, EL; Ferguson, D; Gajda, C; Gracheck, SJ; Hagen, SE; Holler, T; Hupe, D; Iyer, K; Lunney, EA; Markoski, LJ; Nouhan, C; Saunders, J; Sinz, M; Tait, BD; Tummino, PJ; VanderRoest, S; Vara Prasad, JV, 1999)		0.3
" In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models."( 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Brodfuehrer, J; Domagala, J; Gajda, C; Gracheck, SJ; Hagen, SE; Holler, T; Hupe, D; Lovdahl, M; Lunney, EA; Nouhan, C; Pavlovsky, A; Saunders, J; Tait, BD; Urumov, A; VanderRoest, S; Wise, E; Zeikus, E; Zeikus, G, 2001)		0.31

Bioavailability

ExcerptReferenceRelevance
" Cmax and absolute bioavailability of 34S were higher and half-life and time above EC95 were longer compared to 16S."( Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
Boyer, FE; Domagala, JM; Ellsworth, EL; Erickson, JW; Ferguson, D; Gajda, C; Gracheck, SJ; Graham, N; Hagen, SE; Hamilton, HW; Holler, T; Humblet, C; Hupe, D; Lunney, EA; Markoski, LJ; Nouhan, C; Pavlovsky, A; Prasad, JV; Rubin, JR; Steinbaugh, BA; Tait, BD; Tummino, PJ; Urumov, A; Zeikus, E; Zeikus, G, 1999)		0.52
" Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species."( 4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
Brodfuehrer, J; Domagala, J; Gajda, C; Gracheck, SJ; Hagen, SE; Holler, T; Hupe, D; Lovdahl, M; Lunney, EA; Nouhan, C; Pavlovsky, A; Saunders, J; Tait, BD; Urumov, A; VanderRoest, S; Wise, E; Zeikus, E; Zeikus, G, 2001)		0.31

Dosage Studied

ExcerptRelevanceReference
" While the use of currently approved HIV protease inhibitors in concert with drugs that target the reverse transcriptase has dramatically ameliorated the disease state for many individuals, highly-structured dosing regimens accompanied by adverse side-effect profiles have led to a significant level of patient non-compliance."( Non-peptidic HIV protease inhibitors.
Chrusciel, RA; Strohbach, JW, 2004)		0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency43.64120.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency43.64120.173734.304761.8120AID1346859
AR proteinHomo sapiens (human)Potency45.38140.000221.22318,912.5098AID743036; AID743053
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency54.94100.000214.376460.0339AID720691; AID720692
pregnane X nuclear receptorHomo sapiens (human)Potency30.63790.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.93490.000229.305416,493.5996AID743069; AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency43.64120.001019.414170.9645AID743191
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.30600.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency68.58960.000627.21521,122.0200AID743202
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1IC50 (µMol)0.00060.00010.22487.3200AID162030; AID162386
Protease Human immunodeficiency virus 1Ki0.00010.00000.04433.1000AID160312; AID160448
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID54925Inhibition of Cytochrome P450 3A4 at 10 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID27704compound was evaluated for pharmacokinetic parameter, half life period (T1/2)2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54413Inhibition of Cytochrome P450 2C9 at 10 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID25986compound was evaluated for pharmacokinetic parameter, area under curve (AUC)2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID47261In vitro inhibition of HIV-1 (IIIB) cytopathic effects in CEM (human leukemia) cells.1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID160312Compound was tested for binding affinity against HIV protease1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID82746Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with A protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID162030HIV-1 protease inhibition.2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID82750Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with E protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID47268Tested for antiviral activity against HIV-III B strain infected human lymphocyte derived CEM cells1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.
AID82749Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with D protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID82747Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with B protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54603Inhibition of Cytochrome P450 2D6 at 1 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID25745Compound was evaluated for pharmacokinetic parameter, area under curve (AUC)2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54926Inhibition of Cytochrome P450 3A4 at 1 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID54602Inhibition of Cytochrome P450 2D6 at 10 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID28518Compound was evaluated for pharmacokinetic parameter, Cmax in rat at 25 mg/kg po2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID47115Antiviral activity in HIV infected CEM cells as effective concentration at which 50% of the cells are protected from cytopathic effect.2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID162386Tested in vitro for HIV protease (PR) binding affinity1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID235231Therapeutic index was determined1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.
AID82748Fold increase in EC50 for antiviral activity against HIV Protease-Resistant strains with C protease amino acid substitutions2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54414Inhibition of Cytochrome P450 2C9 at 100 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID29835Bioavailability2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54417Inhibition of Cytochrome P450 2C9 at 1 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID28101Compound was evaluated for pharmacokinetic parameter, Cmax2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID29728compound was evaluated for pharmacokinetic parameter, Tmax2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54924Inhibition of Cytochrome P450 3A4 at 100 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID235742Therapeutic index was determined1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID160448In vitro binding affinity against HIV protease at pH 6.2 was determined1999Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl,5-methylphenyl thio) moiety: antiviral activities and pharmacokinetic properties.
AID47617Toxicity measured in CEM cells in the absence of virus.2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID54601Inhibition of Cytochrome P450 2D6 at 100 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
Nonpeptidic HIV protease inhibitors: 6-alkyl-5,6-dihydropyran-2-ones possessing a novel and achiral 3-(2-t-butyl-5-methyl-4-sulfamate)phenylthio moiety.
AID29533Compound was evaluated for pharmacokinetic parameter, Tmax2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
AID27005Compound was evaluated for pharmacokinetic parameter, half life period (T1/2)2001Journal of medicinal chemistry, Jul-05, Volume: 44, Issue:14
4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		3.1210isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sulfamic acid
sulfamic acid: standard in alkalimetry; RN given refers to parent cpd; structure. sulfamic acid : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to hydroxy and amino groups and by double bonds to two oxygen atoms.		210sulfamic acids
ritonavir
Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.		2101,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas		antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic
dmp 850
DMP 850: structure in first source		3.1210
tetronic acid
tetronic acid: structure; in fifth source		3.1210
indinavir sulfate
Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.		210dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide		HIV protease inhibitor
tipranavir
tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.		3.1210sulfonamideantiviral drug;
HIV protease inhibitor
pnu 103017
PNU 103017: an HIV aspartyl protease inhibitor; structure in first source		3.1210
ConditionIndicatedRelationship StrengthStudiesTrials
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		03.6130
HIV Coinfection
[description not available]		02.9310
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.9310